- Sweden
- /
- Medical Equipment
- /
- OM:STIL
Earnings Miss: Stille AB Missed EPS By 33% And Analysts Are Revising Their Forecasts
It's shaping up to be a tough period for Stille AB (STO:STIL), which a week ago released some disappointing third-quarter results that could have a notable impact on how the market views the stock. Results showed a clear earnings miss, with kr128m revenue coming in 3.7% lower than what the analystsexpected. Statutory earnings per share (EPS) of kr1.41 missed the mark badly, arriving some 33% below what was expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
View our latest analysis for Stille
Following the latest results, Stille's two analysts are now forecasting revenues of kr624.9m in 2025. This would be a sizeable 28% improvement in revenue compared to the last 12 months. Per-share earnings are expected to jump 116% to kr12.21. In the lead-up to this report, the analysts had been modelling revenues of kr631.7m and earnings per share (EPS) of kr12.18 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
With the analysts reconfirming their revenue and earnings forecasts, it's surprising to see that the price target rose 17% to kr271. It looks as though they previously had some doubts over whether the business would live up to their expectations.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Stille's past performance and to peers in the same industry. We can infer from the latest estimates that forecasts expect a continuation of Stille'shistorical trends, as the 22% annualised revenue growth to the end of 2025 is roughly in line with the 24% annual growth over the past five years. Juxtapose this against our data, which suggests that other companies (with analyst coverage) in the industry are forecast to see their revenues grow 18% per year. It's clear that while Stille's revenue growth is expected to continue on its current trajectory, it's only expected to grow in line with the industry itself.
The Bottom Line
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At least one analyst has provided forecasts out to 2026, which can be seen for free on our platform here.
That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Stille (at least 1 which can't be ignored) , and understanding these should be part of your investment process.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:STIL
Stille
Manufactures and markets surgical instruments in Sweden and internationally.
Flawless balance sheet with reasonable growth potential.